Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM Trials.
Journal: European journal of haematology
Published: April 10, 2026
The hematology workforce in the United States: past, present, and strategies for the future.
Journal: Blood advances
Published: April 06, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Journal: Lancet regional health. Americas
Published: March 25, 2026
Novel approaches to the use of hypomethylating agents in myeloid malignancies.
Journal: Epigenomics
Published: September 25, 2025
Smoothened Inhibitor, PF-04449913 Inhibits the Development of Myelofibrosis in a JAK2V617F Transgenic Mouse Model by Reducing TGF-β and MAPK Signaling Pathways.
Journal: Research square
Published: May 19, 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
Journal: Future oncology (London, England)
Published: March 07, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.
Journal: Frontiers in medicine
Published: January 11, 2025
Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDS.
Journal: bioRxiv : the preprint server for biology
Published: November 28, 2024
Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy.
Journal: Science (New York, N.Y.)
Published: October 10, 2024
Last Updated: 09/26/2026